Time-series analysis shows hemoglobin levels affect kidney disease progression in patients with ADPKD, indicating clinical significance.
We enrolled 553 patients with autosomal dominant polycystic kidney disease (ADPKD) to investigate the association between hemoglobin (Hb) levels and kidney outcomes. Renal outcome was defined as a 50% reduction in estimated glomerular filtration rate or the initiation of renal replacement therapy. Survival analyses and logistic regression were used to generate time-series McFadden’s pseudo-R-squared (pseudo-R²) values as a goodness-of-fit index to compare the relative contribution of Hb cut-offs over follow-up time, and the mean pseudo-R² values from the first to the 17th year (1–17Y mean) were calculated to summarize long-term patterns. Multivariable Cox analyses indicated that lower Hb was independently associated with kidney disease progression (per 1 g/dL decrease in Hb, P = 0.0016). The highest 1–17Y mean values were observed for Hb < 12.0 g/dL for the entire cohort (1–17Y mean: 0.1128), Hb < 13 g/dL for men (1–17Y mean: 0.1838), and Hb < 12 g/dL for women (1–17Y mean: 0.1191). These findings suggest that Hb thresholds around 12.0 g/dL overall—and sex-specific thresholds of 13 g/dL in men and 12 g/dL in women—showed relatively stronger and more persistent associations with renal outcomes over follow-up time.
No takes yet. Share an insight, caveat, or question.
Kataoka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: